## AZN: Astrazeneca PLC - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.05 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.35)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. AstraZeneca PLC ADR Rises Monday, Outperforms Market**
- Source: 富途牛牛 | 20251209T031010 | Bullish | Relevance: 99%
-  AstraZeneca's ADR rose on Monday, outperforming the broader market. This report also mentions Unity Software's Q4 earnings, which showed a revenue increase of 35% year-over-year to $609 million, surpassing analyst estimates, despite reporting a quarterly loss of 66 cents per share.

**2. Pillar Biosciences and AstraZeneca Expand Liquid Biopsy Access Partnership to China**
- Source: Yahoo Finance | 20251208T090000 | Bullish | Relevance: 98%
-  Pillar Biosciences and AstraZeneca have expanded their partnership to China, aiming to provide broader access to NGS-based kitted liquid biopsy tumor profiling. This collaboration seeks to improve diagnostic turnaround times and access to precision oncology solutions in China, a country with a significant cancer burden. The initiative involves working with Shanghai Zhengu Biological Technology to support assay validation and implement Pillar's liquid biopsy panels in local hospital laboratories.

**3. Quantbot Technologies LP Reduces Stake in AstraZeneca PLC $AZN**
- Source: MarketBeat | 20251209T121010 | Somewhat-Bullish | Relevance: 98%
-  Quantbot Technologies LP significantly reduced its stake in AstraZeneca PLC by 72.9% in Q2 2025, selling 34,171 shares. Despite this, other institutional investors like Deutsche Bank AG increased their positions, and analysts maintain a "Moderate Buy" rating with a target price of $91.67 for AstraZeneca. The biopharmaceutical company recently surpassed EPS and revenue estimates, reporting $1.19 earnings per share and $15.19 billion in revenue for the quarter.

**4. AstraZeneca is top pharma tip for 2026, with GSK left trailing**
- Source: Proactive financial news | 20251208T233000 | Bullish | Relevance: 98%
- JPMorgan has identified AstraZeneca (LSE:AZN, NASDAQ:AZN) as its top UK healthcare pick for 2026, emphasizing its catalyst-rich pipeline and high likelihood of clinical success. Conversely, GSK (LSE:GSK, NYSE:GSK) is placed at the bottom due to a "muted" growth outlook and limited trial results expected next year. Other companies like Novartis and Bayer are highlighted for their pipelines and potential for re-rating, respectively, while Novo Nordisk remains a favorite.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.7B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 17.8 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -1.2% (minimal 5-day change). Below STRENGTH zone by 5.2pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.7%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.25% (CS: 44) | Neutral |
| RSI_14 | 60.1 | Neutral |
| MACD Histogram | -0.30 | Bearish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 1.193x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $91.51
- **Stop Loss:** $88.35 (3.5% risk)
- **Target:** $97.83 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 158
- **Position Value:** $14,458.58
- **Portfolio %:** 14.46%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*